Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GAIT results

This article was originally published in The Tan Sheet

Executive Summary

Combination glucosamine/chondroitin sulfate "is effective in treating moderate to severe knee pain due to osteoarthritis," Daniel Clegg, University of Utah, et al., conclude in the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT). Findings will be presented at the American College of Rheumatology annual meeting in San Diego, Calif. Nov. 14. Authors evaluated 1,583 patients age 40 and older with knee pain of at least six months duration. Participants were randomized to either glucosamine, chondroitin, a glucosamine/chondroitin combination, celecoxib (Pfizer's Celebrex) or placebo for 24 weeks. Authors used WOMAC pain scores to determine the amount of relief experienced by each patient...

You may also be interested in...



GAIT Authors Seek Further Study Of Moderate-To-Severe Arthritis Sufferers

Authors of the GAIT study have submitted a proposal to further evaluate the effects of glucosamine and chondroitin on osteoarthritis patients by focusing specifically on those with moderate-to-severe pain, according to the study's lead researcher

Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell

Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February. 

Topics

UsernamePublicRestriction

Register

PS098824

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel